Leidos   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Reston VA United States (1969)

Organization Overview

First Clinical Trial
2010
NCT01227967
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., USA | Leidos | Leidos Biomedical Research, Inc. | Leidos Biomedical Research, Inc. in support of Clinical Research Section, LIR, NIAID, Natinal Institutes of Health | Leidos Biomedical Research, Inc. in support of Laboratory of Immunoregulation, NIAID, NIH | Leidos, Inc. | Leidos Life Sciences

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alphavirus Infections (Phase 1)

Chikungunya Fever (Phase 2)

Communicable Diseases (Phase 2)

Encephalitis (Phase 1)

Encephalomyelitis, Eastern Equine (Phase 1)

Encephalomyelitis, Equine (Phase 1)

Encephalomyelitis, Venezuelan Equine (Phase 1)

Encephalomyelitis, Western Equine (Phase 1)

Flaviviridae Infections (Phase 2)

Flavivirus Infections (Phase 2)

Hemorrhagic Fever, Ebola (Phase 1)

Hemorrhagic Fevers, Viral (Phase 1)

HIV Infections (Phase 1)

Infections (Phase 2)

Influenza, Human (Phase 2)

RNA Virus Infections (Phase 2)

Uterine Cervical Neoplasms (Phase 3)

Virus Diseases (Phase 2)

Zika Virus Infection (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 18